慢性牙周炎伴咬合创伤患者龈沟液炎性因子表达及与骨代谢指标的相关性研究

目的　观察慢性牙周炎伴咬合创伤患者龈沟液炎性因子表达情况,并分析与骨代谢指标的相关性。方法　选取2020年1~4月收治的52例慢性牙周炎伴咬合创伤患者为伴咬伤组,另选取同期慢性牙周炎52例为不伴咬伤组。伴咬伤组和不伴咬伤组均于治疗前采用酶联免疫吸附法进行龈沟液中炎性因子(TNF-α,IL-1β,CRP和IL-6)和骨代谢指标(BALP,CTX-1和tPINP)检测,采用放射免疫法进行骨代谢指标BGP表达值检测。比较伴咬伤组和不伴咬伤组龈沟液炎性因子、骨代谢指标表达差异,并采用Pearson相关系数分析描述龈沟液炎性因子表达及与骨代谢指标的相关性。结果　伴咬伤组的龈沟液炎性因子(TNF-α,CRP,IL-1β和IL-6)表达值、骨代谢指标(BGP,CTX1和tPINP)表达值均高于不伴咬伤组,差异均有统计学意义(t = 5.499 ~ 28.161,均P<0.05)。伴咬伤组的骨代谢指标(BGP)表达值高于不伴咬伤组,差异有统计学意义(t = 4.054,P<0.05)。龈沟液炎性因子(TNF-α,CRP,IL-1β和IL-6)表达值与龈沟液BALP表达值呈负相关性(r = - 0.813 ~ -0.694,均P<0.05),与龈沟液BGP表达值呈正相关(r =0.708 ~ 0.767,均P<0.05),与龈沟液CTX1表达值呈正相关(r =0.709 ~ 0.791,均P<0.05),与龈沟液tPINP表达值呈正相关(r = 0.695 ~ 0.842,均P<0.05)。结论　伴咬合创伤可加重慢性牙周炎患者机体炎性反应,而伴咬合创伤导致的炎性反应也可对慢性牙周炎患者骨代谢水平产生影响,伴咬合创伤对慢性牙周炎病情的促进作用需给予临床重视。     

人卵巢癌细胞SKOV3中壳多糖酶3样蛋白1的表达和对细胞增殖及侵袭的影响实验研究

目的　探讨壳多糖酶3 样蛋白1（chitinase-3-like-protein-1, CHI3L1）在卵巢癌细胞SKOV3 中的表达和对SKOV3 细胞增殖和侵袭的影响。方法　构建pll3.7-CHI3L1 shRNA 重组质粒,转染卵巢癌细胞SKOV3,使得卵巢癌细胞中的CHI3L1 基因沉默;pll3.7-CHI3L1 shRNA 重组质粒转染卵巢癌细胞SKOV3,同时转染空载质粒作为阴性对照,通过Western Blot 检测SKOV3 细胞中CHI3L1 蛋白表达水平;平板细胞克隆形成试验观察对卵巢癌细胞SKOV3 增殖的影响;采用Transwell 实验检测卵巢癌细胞SKOV3 侵袭能力的变化。结果　成功构建pll3.7-CHI3L1 shRNA 重组质粒,转染卵巢癌细胞SKOV3 后,观察到大量的绿色荧光细胞,且和对照组相比,pll3.7-CHI3L1 shRNA 转染组卵巢癌细胞SKOV3 中CHI3L1 蛋白表达水平下降,卵巢癌SKOV3 细胞的克隆数目减少,侵袭能力下降。结论　卵巢癌细胞SKOV3 中CHI3L1 的表达下调,抑制了SKOV3 细胞的增殖和侵袭能力。     

妊娠并发甲减患者血清脂蛋白相关磷脂酶A2水平与母婴预后的相关性分析

目的　探讨血清脂蛋白相关磷脂酶A2（LP-PLA2）水平在妊娠并发甲减患者中的表达,并分析其与母婴预后的关系。方法　选取2018年7月~2020年7月妊娠并发甲减患者105例作为研究对象,其中妊娠并发临床甲减46例作为临床甲减组,妊娠并发亚临床甲减59例作为亚临床甲减组,另选取同期产检健康者50例作为对照组。采用酶联免疫吸附法检测血清LP-PLA2水平,采用全自动生化分析仪检测血清三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和高密度脂蛋白胆固醇（HDL-C）水平,并记录母婴结局。采用Pearson检验分析妊娠并发甲减患者血清LP-PLA2与血脂水平的相关性;采用ROC曲线分析血清LP-PLA2及血脂水平对妊娠并发甲减患者母婴不良结局的预测价值。结果　三组患者血清LP-PLA2,TG,TC和LDL-C和HDL-C水平比较,差异均有统计学意义（F=31.177,97.170,18.242,25.286和9.423,均P＜0.05）;血清LP-PLA2,TG,TC,LDL-C水平由高到低为临床甲减组、亚临床甲减组、对照组,血清HDL-C水平由高到低为对照组、亚临床甲减组、临床甲减组,两两比较差异均有统计学意义（均P＜0.05）。妊娠并发甲减患者血清LP-PLA2与TG,TC,LDL-C水平均呈正相关（r=0.504,0.481和0.552,均P＜0.05）,与HDL-C水平呈负相关（r=-0.433,P＜0.05）。亚临床甲减组和临床甲减组患者总母婴不良结局发生率分别为69.49%和78.26%,均明显高于对照组（32.00%）,差异有统计学意义（均P＜0.05）。母婴不良结局组患者血清LP-PLA2,TG,TC和LDL-C水平均明显高于母婴正常结局组（t=4.389,4.072,2.662,3.099,均P＜0.05）,血清HDL-C水平明显低于母婴正常结局组（t=3.131,P＜0.05）。血清LP-PLA2水平预测妊娠并发甲减患者母婴不良结局的价值（曲线下面积0.942,敏感度和特异度分别为85.50%和96.40%）高于血脂指标。结论　妊娠并发甲减患者血清LP-PLA2水平升高,可作为评估母婴不良结局的血清指标。     

急性脑缺血患者血清IGFBP-4和PLGF水平与颈动脉斑块不稳定性的相关性研究

目的　探讨急性脑缺血(acute cerebral ischemia,ACI)患者血清胰岛素样生长因子结合蛋白-4(insulin like growth factor binding protein-4,IGFBP-4)和胎盘生长因子(placental growth factor,PLGF)水平的变化与颈动脉斑块不稳定性的相关性。方法　收集2018年6月～2020年6月在商洛市中心医院和咸阳市第一人民医院神经内科住院治疗的105例颈动脉斑块患者作为研究对象。依据患者是否发生ACI分为ACI组(57例)和非ACI组(48例)。采用酶联免疫吸附法检测血清IGFBP-4和PLGF水平。所有研究对象均接受颈动脉超声造影检查。观察患者的斑块厚度、长度、剪切波速度(shear wave velocity,SWV)及回声强度(echo intensity,EI)。比较分析以上指标的变化与颈动脉斑块不稳定性的相关性。结果　非ACI组和ACI组的血清IGFBP-4和PLGF水平分别为5.39±1.43ng/ml,7.27±1.83ng/ml和51.09±3.66ng/L,83.21±7.97ng/L。与非ACI组比较,ACI组的IGFBP-4和PLGF水平显著增高,差异有统计学意义(t=10.210~27.237,均P=0.000)。相关性分析显示,ACI组和非ACI组的血清IGFBP-4和PLGF水平分别呈正相关性(r=0.796,0.750,均P<0.01)。非ACI组的 IGFBP-4和PLGF水平分别与SWV呈负相关性,与EI呈正相关性(rIGFBP-4=-0.823,0.835,均P<0.01;rPLGF=-0.794,0.812,均P<0.01)。ACI组的IGFBP-4和PLGF水平分别与SWV呈负相关性,与EI呈正相关性(rIGFBP-4=-0.833,0.851, 均P<0.01; rPLGF=-0.819, 0.827, P均<0.01)。结论　IGFBP-4和PLGF可能参与颈动脉斑块破裂的病理过程。检测血清IGFBP-4和PLGF水平可对患者颈动脉斑块的不稳定性进行评估进而预测ACI的发生。     

Immunohistochemical detection of proliferating cell nuclear antigen in hepatocellular carcinoma

ＩｍｍｕｎｏｈｉｓｔｏｃｈｅｍｉｃａｌｄｅｔｅｃｔｉｏｎｏｆｐｒｏｌｉｆｅｒａｔｉｎｇｃｅｌｎｕｃｌｅａｒａｎｔｉｇｅｎｉｎｈｅｐａｔｏｃｅｌｕｌａｒｃａｒｃｉｎｏｍａＷＡＮＧＤｏｎｇ１，ＳＨＩＪｉｎｇＱｕａｎ２ａｎｄＬＩＵＦｅｎｇＸｕａｎ３Ｓｕ...     

Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)

We investigated the effect of smaller dose, weight-adjusted heparin with earlier monitoring of activated partial thromboplastin time on the incidence of ischemic and hemorrhagic complications in patients with ST-elevation myocardial infarction treated with full-dose tenecteplase. We compared the outcomes of patients enrolled in the Second Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-2; n = 8,461) who received heparin stratified by weight (patients weighing >67 kg received a 5,000-U bolus plus infusion at 1,000 U/hour; those weighing < or =67 kg received a 4,000-U bolus plus infusion at 800 U/hour) with patients in ASSENT-3 who received weight-adjusted heparin (60-U/kg bolus, maximum 4,000 U/hour, followed by a 12-U/kg/hour infusion, maximum 1,000 U/hour). Compared with patients in ASSENT-2, those in ASSENT-3 had similar rates of 30-day mortality, recurrent infarction, and intracranial hemorrhage, less major bleeding (2.2% vs 4.7%, p <0.001), and less refractory ischemia (6.5% vs 8.6%, p <0.001). After adjustment for baseline characteristics, patients in ASSENT-3 had similar rates of 30-day mortality (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.77 to 1.19) and intracranial hemorrhage (OR 1.02, 95% CI 0.61 to 1.69) but less major bleeding (OR 0.49, 95% CI 0.35 to 0.67) than did patients in ASSENT-2. These findings support the use of smaller dose, weight-adjusted heparin in patients with ST-elevation myocardial infarction treated with tenecteplase.     

Quality of diabetes care predicts the development of cardiovascular events: results of the QuED study

Background and aimIn the context of the QuED Study we assessed whether a quality of care summary score was able to predict the development of cardiovascular (CV) events in patients with type 2 diabetes.Methods and resultsThe score was calculated using process and intermediate outcome indicators (HbA_1c, blood pressure, low-density lipoprotein cholesterol, microalbuminuria) and ranged from 0 to 40. Overall, 3235 patients were enrolled, of whom 492 developed a CV event after a median follow-up of 5 years. The incidence rate (per 1000 person-years) of CV events was 62.4 in patients with a score ≤10, 54.8 in those with a score between 15 and 20, and 39.8 in those with a score >20. In adjusted multilevel regression models, the risk to develop a CV event was 89% greater in patients with a score of ≤10 (rate ratio [RR] = 1.89; 95% confidence interval [CI] 1.43–2.50) and 43% higher in those with a score between 10 and 20 (RR = 1.43; 95% CI 1.14–1.79), as compared to those with a score >20. A difference between centers of 5 points in the mean quality score was associated with a difference of 16% in CV event risk (RR = 0.84; 95% CI 0.72–0.98).ConclusionOur study documented for the first time a close relationship between a score of quality of diabetes care and long-term outcomes.     

Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment

Background

Clinical trials demonstrate significant benefit from cholesterol management for patients with type 2 diabetes. The aim of this work was to explore the correlates of lipid management in patients with type 2 diabetes, including the subjective beliefs of physicians, setting of care, and patient-related factors.

Methods

This longitudinal outcomes research study involved 2359 patients with type 2 diabetes recruited by 111 general practitioners and 214 physicians practicing in diabetes clinics. Physicians' beliefs were assessed through a questionnaire administered when the study started in 1998. Main outcome measures were total cholesterol (TC) and LDL cholesterol (LDL-C) levels over 3 years and the proportion of patients treated with lipid-lowering drugs (LLDs).

Results

Less than one-third of the physicians (27%) stated that they routinely started pharmacologic therapy for TC values ≥200 mg/dL (more aggressive), whereas 46% considered a TC level ≥240 mg/dL as the threshold for the initiation of treatment (less aggressive). During 3 years of observation, mean TC and LDL-C levels decreased from 215 ± 40 mg/dL to 203 ± 37 mg/dL and from 135 ± 36 mg/dL to 126 ± 35 mg/dL respectively, while the proportion of patients treated with LLDs increased from 13.2% to 24.6%; in particular, among individuals cared for by the more aggressive physicians, 30.0% were taking LLDs after 3 years, while only 17.7% of those followed by the less aggressive physicians and 18.1% of those followed by >1 physician were being treated with LLDs. Multilevel analysis showed that physicians' beliefs were an independent predictor of TC levels over the 3-year period. In patients treated with LLDs, TC levels decreased on average by 14%, and LDL-C levels decreased by 20%.

Conclusion

Our data show that physicians' beliefs in more aggressive management strategies will result in better mean TC values over a 3-year period.     

EPCs在MSCs向肝样细胞转化中作用的初步探讨

目的：探讨内皮前体细胞(endothelial precursor cells, EPCs)在间充质干细胞(mesenchymal stem cells, MSCs)向肝样细胞转化中的作用。方法：分离培养SD大鼠MSCs和EPCs,取第3代MSCs向肝样细胞转化培养,培养过EPCs的无血清及因子的培养基(endothelial progenitor cell-conditioned medium, EPCs-CM)、无血清的α-最低必需培养基(alpha minimal essential medium, α-MEM)分别与肝细胞转化培养基按1∶1比例配置,作为实验组和模型对照组,正常α-MEM培养基为空白对照组,分别观察细胞形态及数量变化;在培养3、5、7、9 d时应用免疫荧光检测甲胎蛋白(alpha fetoprotein, AFP)、清蛋白(albumin, ALB)的表达。结果：空白对照组MSCs形态无明显变化;实验组与模型对照组细胞均出现肝样细胞形态。空白对照组未见AFP、ALB表达,模型对照组和实验组在3、5、7、9 d AFP、ALB表达水平均增高,其中实验组比模型对照组AFP、ALB水平增高明显。结论：EPCs在MSCs向肝样细胞转化中可能起一定的促进作用。